Clinical Trial Update: Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe [Phase 4]

View source ↗

Summary

A Phase 4 placebo-controlled trial evaluated omega-3 fatty acids in subjects at ultra-high risk for psychosis and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ultra High Risk For Psychosis

Drugs mentioned

• Omega-3 fatty acids (omega-3 fatty acids)

Snippet

Sponsor: Rene Kahn | Conditions: Ultra High Risk for Psychosis | Phase 4 | Status: COMPLETED